NASDAQ:SYRS – Knox Daily

Analysts Viewpoint

Syros Pharmaceuticals Inc [NASDAQ: SYRS] Sees Increase in Stock Value

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

H.C. Wainwright Upgrades Syros Pharmaceuticals Inc (SYRS) to a Buy from a Neutral

In a filing, Syros Pharmaceuticals Inc revealed its Affiliate Flagship Pioneering Fund VII, acquired Company’s shares for reported $0.27 million

Analysts Viewpoint

Taking a look at what insiders are doing to gauge the Syros Pharmaceuticals Inc (SYRS)’s direction

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Insiders Updates

Analysts review Syros Pharmaceuticals Inc’s rating

Syros Pharmaceuticals Inc’s recent filing unveils that its Affiliate Flagship Pioneering Fund VII, acquired Company’s shares for reported $0.27 million

Stock Earnings

The Attractiveness of Investing In Syros Pharmaceuticals Inc (SYRS) is Growing

Syros Pharmaceuticals Inc’s recently made public that its Affiliate Flagship Pioneering Fund VII, acquired Company’s shares for reported $0.27 million

Stock Earnings

Syros Pharmaceuticals Inc [SYRS] Records 200-Day SMA of $3.1990

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Syros Pharmaceuticals

Stock Earnings

H.C. Wainwright Upgrades Syros Pharmaceuticals Inc (SYRS) to a Buy from a Neutral

Syros Pharmaceuticals Inc’s filing revealed that its Director AKKARAJU SRINIVAS acquired Company’s shares for reported $2306.0 on Dec 30 ’24.

Stock Earnings

Examining the Potential Price Growth of Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc’s recently made public that its Director AKKARAJU SRINIVAS acquired Company’s shares for reported $2306.0 on Dec 30

Tag: NASDAQ:SYRS